Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729606 · ClinicalTrials.gov registry record · Phase 3
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 471
- Enrollment target
NCT06729606 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 471 participants.
The verdict
NCT06729606, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 471 participants
- Enrollment target
Study Summary
This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Aviptadil plus current standard of care (SOC), or with placebo plus current SOC.
Interventions
- DRUG Corticosteroid
- BIOLOGICAL Aviptadil
- BIOLOGICAL Aviptadil Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06729606
The ClinicalTrials.gov registry entry for NCT06729606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Corticosteroid is the first listed.
NCT06729606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06729606 about?
NCT06729606 is a clinical study titled "Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)". This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Aviptadil plus current standard of care (SOC), or with placebo plus curren...
What is the current status of trial NCT06729606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 471 participants. The study started on 2021-04-20. Estimated completion is 2022-11-20.
What interventions are being tested in trial NCT06729606?
The interventions under investigation include: Corticosteroid (DRUG), Aviptadil (BIOLOGICAL), Aviptadil Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06729606?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.